Defilade Capital Management
Defilade Capital Management reported 39 stocks worth $747M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are LLY (6.3%), PFE (5.7%) and VEEV (5.6%). Compared with Q1 2026, the fund opened new positions in VEEV, BMRN and BAX, added to LLY, PFE and PTCT, trimmed ZBH, ELAN and RVMD and sold out of HSIC, BDX and DXCM.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  LLY Eli Lilly & Co | $46.9M | 6.3% | 39K | +18K (+89%) | 3 of 3 | |
| 2 |  PFE Pfizer Inc | $42.7M | 5.7% | 1.8M | +308K (+21%) | 3 of 3 | |
| 3 |  VEEV Veeva Sys Inc Class Class A | $42M | 5.6% | 237K | New position | 1 of 3 | |
| 4 |  BMRN Biomarin Pharmaceutical Inc | $39M | 5.2% | 682K | New position | 1 of 3 | |
| 5 |  PTCT Ptc Therapeutics Inc | $35.4M | 4.7% | 434K | +58K (+15%) | 2 of 3 | |
| 6 |  BAX Baxter Intl Inc | $31.1M | 4.2% | 1.5M | New position | 1 of 3 | |
| 7 |  INSM Insmed Inc | $30M | 4.0% | 282K | +87K (+45%) | 3 of 3 | |
| 8 |  ZBH Zimmer Biomet Hldgs Inc | $27.3M | 3.7% | 317K | −262K (−45%) | 2 of 3 | |
| 9 |  PODD Insulet Corp | $26.9M | 3.6% | 177K | New position | 1 of 3 | |
| 10 |  TMO Thermo Fisher Scientific Inc | $26M | 3.5% | 52K | New position | 1 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 HSIC Henry Schein Inc | $46M | 624K |
 BDX Becton Dickinson & Co | $43.9M | 279K |
 DXCM Dexcom Inc | $33.8M | 539K |
 ISRG Intuitive Surgical Inc | $31.2M | 68K |
 NBIX Neurocrine Biosciences Inc | $27.7M | 210K |
🔒 Free account: see all 12.
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Defilade Capital Management 13F FAQ
What does Defilade Capital Management own?
Defilade Capital Management reported 39 stocks worth $747M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are LLY (6.3%), PFE (5.7%) and VEEV (5.6%). The table above lists every position in the filing (the top 10 without an account).
What did Defilade Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 20 new positions, 8 added to, 10 trimmed and 12 sold out. New positions include VEEV, BMRN and BAX. It sold all of HSIC, BDX and DXCM.
When will Defilade Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Defilade Capital Management's portfolio worth?
The Q2 2026 filing reports $747M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.